Suppr超能文献

造血干细胞:了解释放造血干细胞移植治疗潜力的机制。

Hematopoietic stem cells: Understanding the mechanisms to unleash the therapeutic potential of hematopoietic stem cell transplantation.

作者信息

Aljagthmi Amjad Ahmed, Abdel-Aziz Amal Kamal

机构信息

Research center, King Faisal Specialist Hospital and Research Centre, Jeddah, 21499, Kingdom of Saudi Arabia.

Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, 11566, Egypt.

出版信息

Stem Cell Res Ther. 2025 Feb 10;16(1):60. doi: 10.1186/s13287-024-04126-z.

Abstract

Hematopoietic stem cell transplantation (HSCT) is a promising approach in regenerative medicine and serves as a standard treatment for different malignant and non-malignant conditions. Despite its widespread applications, HSCT is associated with various complications that compromise patients' lives and pose considerable risks of morbidity and mortality. Understanding the molecular physiology of HSCs is fundamental to ultimately enhance the mobilization, engraftment and differentiation of HSCs, thus unleashing the full therapeutic potential of HSCT in the treated patients. This review outlines the current understanding of HSC biology and its relevance to the clinical challenges associated with HSCT. Furthermore, we critically discuss the pros and cons of the preclinical murine models exploited in the HSCT field. Understanding the molecular physiology of HSCs will ultimately unleash the full therapeutic potential of HSCT. HSCs derived from induced pluripotent stem cells (iPSCs) might present an attractive tool which could be exploited preclinically and clinically. Nonetheless, further studies are warranted to systematically evaluate their potential in terms of improving the therapeutic outcome and minimizing the adverse effects of HSCT.

摘要

造血干细胞移植(HSCT)是再生医学中一种很有前景的方法,也是治疗各种恶性和非恶性疾病的标准疗法。尽管HSCT应用广泛,但它会引发各种并发症,危及患者生命,并带来相当大的发病和死亡风险。了解造血干细胞(HSCs)的分子生理学对于最终提高造血干细胞的动员、植入和分化至关重要,从而充分发挥HSCT在治疗患者中的全部治疗潜力。本综述概述了目前对造血干细胞生物学的理解及其与HSCT相关临床挑战的相关性。此外,我们批判性地讨论了HSCT领域中使用的临床前小鼠模型的优缺点。了解造血干细胞的分子生理学最终将释放HSCT的全部治疗潜力。源自诱导多能干细胞(iPSCs)的造血干细胞可能是一种有吸引力的工具,可在临床前和临床中加以利用。尽管如此,仍有必要进行进一步研究,以系统评估它们在改善治疗效果和最小化HSCT不良反应方面的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ac16/11809095/feccb18563ed/13287_2024_4126_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验